| Meta-analysis summary statistics for associations meeting genome-wide significance | |||||||
|---|---|---|---|---|---|---|---|
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs174548 | arachidonate (20:4n6) / dihomo-linolenate (20:3n3 or n6) | C/G | 7350 | 0.7 | 0.071 (0.002) | 1.53·10-361 | show |
| rs174535 | 1-arachidonoylglycerophosphocholine* | T/C | 7063 | 0.66 | 0.056 (0.003) | 1.86·10-94 | show |
| rs174548 | arachidonate (20:4n6) | C/G | 7367 | 0.7 | 0.049 (0.003) | 1.43·10-84 | show |
| rs174578 | 1-arachidonoylglycerophosphoethanolamine* | A/T | 7350 | 0.34 | -0.035 (0.003) | 6.12·10-42 | show |
| rs174535 | 1-linoleoylglycerophosphoethanolamine* | T/C | 7369 | 0.67 | -0.044 (0.004) | 2.82·10-36 | show |
| rs174578 | 1-arachidonoylglycerophosphoinositol* | A/T | 7351 | 0.34 | -0.027 (0.003) | 3.02·10-24 | show |
| rs174550 | adrenate (22:4n6) | T/C | 7330 | 0.67 | 0.035 (0.003) | 6.79·10-24 | show |
| rs174556 | eicosapentaenoate (EPA; 20:5n3) | T/C | 7367 | 0.3 | -0.036 (0.004) | 1.97·10-22 | show |
| rs968567 | dihomo-linolenate (20:3n3 or n6) | T/C | 7358 | 0.18 | 0.033 (0.004) | 2.14·10-21 | show |
| rs968567 | 1-eicosatrienoylglycerophosphocholine* | T/C | 7362 | 0.18 | 0.040 (0.005) | 2.84·10-19 | show |
| rs174601 | stearidonate (18:4n3) | T/C | 7330 | 0.34 | -0.034 (0.004) | 7.93·10-16 | show |
| rs174538 | docosapentaenoate (n3 DPA; 22:5n3) | A/G | 7373 | 0.3 | -0.026 (0.004) | 8.9·10-14 | show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations | |
|---|---|
| SNP | rs174548 |
| Chromosomal location | Chr11: 61,327,924 (11q12.2) |
| Gene (distance) | FADS1 (0) |
| Predicted causal gene | FADS1 |
| Gene/protein classification | - |
| Metabolite (Pathway) | arachidonate (20:4n6) (Long chain fatty acid; Lipid) dihomo-linolenate (20:3n3 or n6) (Essential fatty acid; Lipid) |
| Biochemical locus-metabolite relationship | FADS1, FADS2 and FADS3 encode three homologous fatty acid desaturases; FADS1 is a delta-5 desaturase, FADS2 is a delta-6 desaturase, and the catalytic activity of FADS3 is unknown [10601301]. The ratio of arachidonate (20:4n6) to dihomo?linolenate (20:3n3 or n6) represents a product/substrate pair for FADS1. Ratio interpretation: n/a. |
| eQTL associations | FADS1 (H), FADS1 (F), FADS3 (H) † |
† F = adipose tissue; S = skin cells; L = lymphoblastoid cells; H = liver cells;
| Medical information | |
|---|---|
| Complex trait associations | Cholesterol, total [20686565]; Comprehensive strength and appendicular lean mass [22960237]; Crohn's disease [21102463]; Fasting glucose-related traits [20081858]; Fasting glucose-related traits (interaction with BMI) [22581228]; HDL cholesterol [19060906,20864672,20686565]; Hematology traits [23303382]; LDL cholesterol [19060910,20686565]; Lipid metabolism phenotypes [22286219]; Metabolic syndrome [20694148]; Response to statin therapy [20339536]; Resting heart rate [20639392]; Triglycerides [19060906,20864672,20686565] |
| Known metabolite associations | 1-arachidonoylglycerophosphoethanolamine*/1-linoleoylglycerophosphoethanolamine* [21886157]; PC aa C36:3/PC aa C36:4 [20037589]; PC aa C36:4 [19043545]; Metabolite levels [19043545,23281178,22916037]; Oleic acid (18:1n-9) plasma levels [23362303]; Palmitoleic acid (16:1n-7) plasma levels [23362303]; Phospholipid levels (plasma) [22359512,21829377]; Stearic acid (18:0) plasma levels [23362303]; PC 38:4 [23823483] |
| Inborn error of metabolism | - |
| Pharmacological information | |
|---|---|
| ChEMBL ID | - |
| Drug information | Compounds with activity in ChEMBL for FADS2 |
| Locus information for top associated metabolite | |
|---|---|
HapMap2 imputation![]() | 1KGP imputation![]() |








